Duration of Leg Nerve Blocks With Dexamethasone Added to Local Anesthetic
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01511211 |
Recruitment Status :
Withdrawn
(Other researchers have published results on a similar trial)
First Posted : January 18, 2012
Last Update Posted : September 12, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pain Total Knee Arthroplasty | Drug: Dexamethasone Drug: Ropivacaine | Phase 4 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Effect of Dexamethasone on Duration of Analgesia After Ultrasound-Guided Femoral, Obturator, and Popliteal Blocks With Ropivacaine in Total Knee Arthroplasty |
Study Start Date : | September 2012 |
Actual Primary Completion Date : | August 2013 |
Actual Study Completion Date : | August 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: Ropivacaine + Dexamethasone Combination |
Drug: Dexamethasone
2 cc of 4 mg/cc dexamethasone will be added to 38 cc of 0.5% ropivacaine solution. Of this combination, 15 cc will be used for a femoral nerve block, 20 cc for the popliteal nerve block, and 5 cc for the obturator nerve block. In addition, 2 cc of normal saline will be added to the patient's IV to maintain blinding.
Other Name: Decadron |
Active Comparator: Ropivacaine-Only Block |
Drug: Ropivacaine
2 cc of normal saline will be added to 38 cc of 0.5% ropivacaine solution. Of this combination, 15 cc will be used for the femoral nerve block, 20 cc for the popliteal nerve block, and 5 cc for the obturator nerve block. In addition, 2 cc of 4 mg/cc dexamethasone will be added to the patient's IV.
Other Name: Naropin |
- Duration of Analgesia [ Time Frame: 72 hours or first report of pain in the knee which ever is earliest ]Duration of analgesia defined as the time interval between the end of local anesthetic injection and the patient's first report of pain in the knee.
- Duration of motor blockade [ Time Frame: 72 hour or first return of motor function ]Time interval between the end of local anesthetic injection and the patient's first report of return in motor function in femoral, obturator and sciatic distribution
- Duration of sensory blockade [ Time Frame: 72 hours or first report of sensory recovery ]Time interval between the end of local anesthetic injection and the patient's first report of return in any sensation in the distribution of femoral and sciatic distribution
- Complete sensory return [ Time Frame: 72 hours or when the patient first reports complete sensation ]interval between the end of local anesthetic injection and the patient's first report of return in complete sensation in the distribution of femoral and sciatic distribution

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- American Society of Anesthesiologists physical status I to III,
- Aged 18 and above,
- Undergoing total knee replacement.
Exclusion Criteria:
- Body mass index of more than 45 kg/m2 (higher chance of failure)
- Weight less than 70 kg
- Diabetes
- Injection site deformities
- Infection at the injection site
- Existing peripheral neuropathy
- Allergy to LA agents
- Contraindications to dexamethasone
- Patients with severe PONV
- Patients with peptic ulceration or upper GI bleed of unknown origin
- Coagulopathy
- Any other contraindication to lower limb peripheral nerve block

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01511211
United States, New Mexico | |
University of New Mexico Hospital | |
Albuquerque, New Mexico, United States, 87106 |
Principal Investigator: | Nicholas Lam, MD | University of New Mexico |
Responsible Party: | Nicholas Lam, Associate Professor, University of New Mexico |
ClinicalTrials.gov Identifier: | NCT01511211 |
Other Study ID Numbers: |
UNMLAMLLDEX |
First Posted: | January 18, 2012 Key Record Dates |
Last Update Posted: | September 12, 2013 |
Last Verified: | September 2013 |
Dexamethasone lower limb block ultrasound guided femoral nerve block ultrasound guided obturator nerve block |
ultrasound guided sciatic nerve block ropivacaine total knee arthroplasty Post surgical pain after total knee arthroplasty |
Dexamethasone Ropivacaine Anti-Inflammatory Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Glucocorticoids |
Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents Anesthetics, Local Anesthetics Central Nervous System Depressants Sensory System Agents |